109
Views
1
CrossRef citations to date
0
Altmetric
Research Articles

Mitigative impact of bradykinin potentiating factor isolated from Androctonus amoreuxi scorpion venom and low doses of γ-irradiation on doxorubicin induced hepatotoxicity through ang II/AMPK crosstalk

ORCID Icon, ORCID Icon &
Pages 518-529 | Received 03 Jan 2022, Accepted 01 Mar 2022, Published online: 15 Mar 2022

References

  • Abbas G, Silveira MG, Lindor KD. 2011. Hepatic fibrosis and the renin-angiotensin system. Am J Ther. 18(6):e202–e208.
  • Ashry O, Moustafa M, Baset AAE, Abu Sinna GE, Farouk H. 2012. Outcome of venom bradykinin potentiating factor on rennin-angiotensin system in irradiated rats. Int J Radiat Biol. 88(11):840–845.
  • Bancroft JD, Gamble M. 2008. Theory and practice of histological techniques. China: Elsevier Health Sciences.
  • Bekheet SH, Awadalla EA, Salman MM, Hassan MK. 2013. Prevention of hepatic and renal toxicity with bradykinin potentiating factor (BPF) isolated from Egyptian scorpion venom (Buthus occitanus) in gentamicin treated rats. Tissue Cell. 45(2):89–94.
  • Bengaied D, Ribeiro A, Amri M, Scherman D, Arnaud P. 2017. Reduction of hepatotoxicity induced by doxorubicin. J Integr Oncol. 06(03):2.
  • Burkewitz K, Zhang Y, Mair WB. 2014. AMPK at the nexus of energetics and aging. Cell Metab. 20(1):10–25.
  • Campbell-Thompson M, Dixon L, Wasserfall C, Monroe M, McGuigan J, Schatz D, Crawford J, Atkinson M. 2009. Pancreatic adenocarcinoma patients with localised chronic severe pancreatitis show an increased number of single beta cells, without alterations in fractional insulin area. Diabetologia. 52(2):262–270.
  • Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, Rubino M, Veglia F, Fiorentini C, Cipolla CM. 2010. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 55(3):213–220.
  • Chan YC, Leung PS. 2011. The renin-angiotensin system and reactive oxygen species: implications in pancreatitis. Antioxid Redox Signal. 15(10):2743–2755.
  • Chaudhary D, Khatiwada S, Sah SK, Tamang MK, Bhattacharya S, Jha CB. 2016. Effect of doxorubicin on histomorphology of liver of wistar albino rats. J Pharm Pharmacol. 4:186–190.
  • Chérifi F, Laraba-Djebari F. 2013. Isolated biomolecules of pharmacological interest in hemostasis from Cerastes cerastes venom. J Venom Anim Toxins Incl Trop Dis. 19(1):11.
  • Christ-Crain M, Kola B, Lolli F, Fekete C, Seboek D, Wittman G, Ajodha S, Harvey-White J, Kunos G, Müller B, et al. 2008. AMP-activated protein kinase mediates glucocorticoid- induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J. 22(6):1672–1683.
  • Damodar G, Smitha T, Gopinath S, Vijayakumar S, Rao Y. 2014. An evaluation of hepatotoxicity in breast cancer patients receiving injection doxorubicin. Ann Med Health Sci Res. 4(1):74–79.
  • Deji N, Kume S, Araki S-i, Isshiki K, Araki H, Chin-Kanasaki M, Tanaka Y, Nishiyama A, Koya D, Haneda M, et al. 2012. Role of angiotensin II-mediated AMPK inactivation on obesity-related salt-sensitive hypertension. Biochem Biophys Res Commun. 418(3):559–564.
  • Duport P. 2003. A database of cancer induction by low-dose radiation in mammals: overview and initial observations. IJLR. 1(1):120–131.
  • Feng X, Luo Z, Ma L, Ma S, Yang D, Zhao Z, Yan Z, He H, Cao T, Liu D, et al. 2011. Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-δ/AMPK pathway . J Cell Mol Med. 15(7):1572–1581.
  • Ferreira S. 1965. A bradykinin-potentiating factor (bpf) present in the venom of bothrops jararca . Br J Pharmacol Chemother. 24(1):163–169.
  • Gao F, Chen J, Zhu H. 2018. A potential strategy for treating atherosclerosis: improving endothelial function via AMP-activated protein kinase. Sci China Life Sci. 61(9):1024–1029.
  • Gavras I. 1992. Bradykinin-mediated effects of ACE inhibition. Kidney Int. 42(4):1020–1029.
  • Graham RLJ, Graham C, McClean S, Chen T, O'Rourke M, Hirst D, Theakston D, Shaw C. 2005. Identification and functional analysis of a novel bradykinin inhibitory peptide in the venoms of New World Crotalinae pit vipers. Biochem Biophys Res Commun. 338(3):1587–1592.
  • Grossman E, Messerli FH, Neutel JM. 2000. Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors? Arch Intern Med. 160(13):1905–1911.
  • Hamlaoui S, Mokni M, Limam N, Carrier A, Limam F, Amri M, Marzouki L, Aouani E. 2012. Resveratrol protects against acute chemotherapy toxicity induced by doxorubicin in rat erythrocyte and plasma. J Physiol Pharmacol. 63(3):293–301.
  • Hardie DG, Ross FA, Hawley SA. 2012. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 13(4):251–262.
  • Hasan HF, Radwan RR, Galal SM. 2020. Bradykinin-potentiating factor isolated from Leiurus quinquestriatus scorpion venom alleviates cardiomyopathy in irradiated rats via remodelling of the RAAS pathway . Clin Exp Pharmacol Physiol. 47(2):263–273.
  • Hayashi MA, Camargo AC. 2005. The Bradykinin-potentiating peptides from venom gland and brain of Bothrops jararaca contain highly site specific inhibitors of the somatic angiotensin-converting enzyme. Toxicon. 45(8):1163–1170.
  • Ibrahim MA, Ashour OM, Ibrahim YF, El-Bitar HI, Gomaa W, Abdel-Rahim SR. 2009. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res. 60(5):373–381.
  • Ikeda U, Maeda Y, Kawahara Y, Yokoyama M, Shimada K. 1995. Angiotensin II augments cytokine-stimulated nitric oxide synthesis in rat cardiac myocytes. Circulation. 92(9):2683–2689.
  • Ina Y, Tanooka H, Yamada T, Sakai K. 2005. Suppression of thymic lymphoma induction by life-long low-dose-rate irradiation accompanied by immune activation in C57BL/6 mice. Radiat Res. 163(2):153–158.
  • Jiang SY, Xu M, Ma XW, Xiao H, Zhang YY. 2010. A distinct AMP-activated protein kinase phosphorylation site characterizes cardiac hypertrophy induced by L-thyroxine and angiotensin II. Clin Exp Pharmacol Physiol. 37(9):919–925.
  • Kassner N, Huse K, Martin H-J, Gödtel-Armbrust U, Metzger A, Meineke I, Brockmöller J, Klein K, Zanger UM, Maser E, et al. 2008. Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos. 36(10):2113–2120.
  • Kojima S, Matsuki O, Nomura T, Yamaoka K, Takahashi M, Niki E. 1999. Elevation of antioxidant potency in the brain of mice by low-dose γ-ray irradiation and its effect on 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced brain damage. Free Radic Biol Med. 26(3-4):388–395.
  • Kumar D, Kirshenbaum LA, Li T, Danelisen I, Singal PK. 2001. Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. Antioxid Redox Signal. 3(1):135–145.
  • Kumar R, Kumar A, Sharma R, Baruwa A. 2010. Pharmacological review on natural ACE inhibitors. Der Pharmacia Lettre. 2(2):273–293.
  • Laher I. 2014. Systems biology of free radicals and antioxidants. Berlin/Heidelberg: Springer.
  • Linz W, Wohlfart P, Schölkens BA, Malinski T, Wiemer G. 1999. Interactions among ACE, kinins and NO. Cardiovasc Res. 43(3):549–561.
  • Liu J, Li X, Lu Q, Ren D, Sun X, Rousselle T, Li J, Leng J. 2019. AMPK: a balancer of the renin–angiotensin system. Biosci Rep. 39(9): 1–18.
  • Ma H, Kong J, Wang Y-L, Li J-L, Hei N-H, Cao X-R, Yang J-J, Yan W-J, Liang W-J, Dai H-Y, et al. 2017. Angiotensin-converting enzyme 2 overexpression protects against doxorubicin-induced cardiomyopathy by multiple mechanisms in rats. Oncotarget. 8(15):24548–24563.
  • Mansour HH, El Kiki SM, Galal SM. 2017. Metformin and low dose radiation modulates cisplatin-induced oxidative injury in rat via PPAR-γ and MAPK pathways. Arch Biochem Biophys. 616:13–19.
  • Miranda KM, Espey MG, Wink DA. 2001. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide. 5(1):62–71.
  • Nagai K, Fukuno S, Oda A, Konishi H. 2016. Protective effects of taurine on doxorubicin-induced acute hepatotoxicity through suppression of oxidative stress and apoptotic responses. Anticancer Drugs. 27(1):17–23.
  • Ribeiro-Oliveira A, Marques MB, Vilas-Boas WW, Guimarães J, Coimbra CC, Anjos AP, Fóscolo RB, Santos R, Thomas JD, Igreja SM, et al. 2015. The effects of chronic candesartan treatment on cardiac and hepatic adenosine monophosphate-activated protein kinase in rats submitted to surgical stress. J Renin Angiotensin Aldosterone Syst. 16(3):481–487.
  • Rifai N. 2017. Tietz textbook of clinical chemistry and molecular diagnostics-e-book. St. Louis (MI): Elsevier Health Sciences.
  • Rossi R, Milzani A, Dalle-Donne I, Giannerini F, Giustarini D, Lusini L, Colombo R, Di Simplicio P. 2001. Different metabolizing ability of thiol reactants in human and rat blood: biochemical and pharmacological implications. J Biol Chem. 276(10):7004–7010.
  • Salman MM, Kotb AM, Haridy MA, Hammad S. 2016. Hepato- and nephroprotective effects of bradykinin potentiating factor from scorpion (Buthus occitanus) venom on mercuric chloride-treated rats . Excli J. 15:807–816.
  • Stuck BJ, Lenski M, Böhm M, Laufs U. 2008. Metabolic switch and hypertrophy of cardiomyocytes following treatment with angiotensin II are prevented by AMP-activated protein kinase. J Biol Chem. 283(47):32562–32569.
  • Szczepanska-Sadowska E, Czarzasta K, Cudnoch-Jedrzejewska A. 2018. Dysregulation of the renin-angiotensin system and the vasopressinergic system interactions in cardiovascular disorders. Curr Hypertens Rep. 20(3):19.
  • Tarpey MM, Fridovich I. 2001. Methods of detection of vascular reactive species: nitric oxide, superoxide, hydrogen peroxide, and peroxynitrite. Circ Res. 89(3):224–236.
  • Thomas RL, Roberts DJ, Kubli DA, Lee Y, Quinsay MN, Owens JB, Fischer KM, Sussman MA, Miyamoto S, Gustafsson ÅB. 2013. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev. 27(12):1365–1377.
  • Wang B, Ohyama H, Shang Y, Tanaka K, Aizawa S, Yukawa O, Hayata I. 2004. Adaptive response in embryogenesis: V. Existence of two efficient dose-rate ranges for 0.3 Gy of priming irradiation to adapt mouse fetuses. Radiat Res. 161(3):264–272.
  • Wang L, Zhang T-P, Zhang Y, Bi H-L, Guan X-M, Wang H-X, Wang X, Du J, Xia Y-L, Li H-H. 2016. Protection against doxorubicin-induced myocardial dysfunction in mice by cardiac-specific expression of carboxyl terminus of hsp70-interacting protein. Sci Rep. 6(1):28399–28314.
  • Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B. 1996. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 49(5):1304–1313.
  • Xiao Y, Ye J, Zhou Y, Huang J, Liu X, Huang B, Zhu L, Wu B, Zhang G, Cai Y. 2018. Baicalin inhibits pressure overload-induced cardiac fibrosis through regulating AMPK/TGF-β/Smads signaling pathway. Arch Biochem Biophys. 640:37–46.
  • Yoshida D, Higashiura K, Shinshi Y, Satoh K, Hyakkoku M, Yoshida H, Miyazaki Y, Ura N, Shimamoto K. 2009. Effects of angiotensin II receptor blockade on glucose metabolism via AMP-activated protein kinase in insulin-resistant hypertensive rats. J Am Soc Hypertens. 3(1):3–8.
  • Zeb A, Ullah F. 2016. A simple spectrophotometric method for the determination of thiobarbituric acid reactive substances in fried fast foods. J Anal Methods Chem. 2016:9412767.
  • Zhang W, Li C, Liu B, Wu R, Zou N, Xu Y-Z, Yang Y-Y, Zhang F, Zhou H-M, Wan K-Q, et al. 2013. Pioglitazone upregulates hepatic angiotensin converting enzyme 2 expression in rats with steatohepatitis. Ann Hepatol. 12(6):892–900.
  • Zhong J, Guo D, Chen CB, Wang W, Schuster M, Loibner H, Penninger JM, Scholey JW, Kassiri Z, Oudit GY. 2011. Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2 . Hypertension. 57(2):314–322.
  • Zhu R, Zeng G, Chen Y, Zhang Q, Liu B, Liu J, Chen H, Li M. 2013. Oroxylin A accelerates liver regeneration in CCl4-induced acute liver injury mice . PLoS One. 8(8):e71612.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.